Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator - a CRDMO combining contract research, development and manufacturing services across the drug development pathway. The company was founded in 1990 as a spin-out from the University of Nottingham and retains academic research roots. It employs more than 1,000 experts across operations in the United Kingdom and the United States, and works with clients ranging from emerging biotechnology companies to Fortune 100 pharmaceutical corporations.

Its central technical offering is Translational Pharmaceutics®, a proprietary platform that integrates clinical activities with real-time cGMP drug product manufacturing, removing the hand-offs between them to shorten the path from candidate selection to commercial supply. Supporting services span drug formulation development, clinical pharmacology, cGMP drug product manufacturing, Phase I/IIa clinical study operations and commercial drug manufacturing. The company's early-phase clinical work has received industry recognition for excellence in Phase I clinical studies.

The firm describes its mission as "bringing molecules to cures, fast", and cites scientific integrity, agility and collaboration as operating principles. It has received multiple CRO Leadership Awards and CDMO Leadership Awards. More than 35 years after its founding, Quotient Sciences continues to serve pharmaceutical and biotechnology clients under a single integrated research, development and manufacturing model.